Industry Insights

  1. Unified Patient Apps: The Future Of Trial Simplicity 11/12/2025

    A unified patient app streamlines clinical trial participation by combining scheduling, questionnaires, travel, and payments—reducing burden, improving engagement, and supporting better retention and data quality.

  2. Heading For An M&A? Understand The Risks And Mitigation Strategies For Clinical Trial Agreements 11/10/2025

    Learn the key considerations to anticipate and mitigate risks that CTAs and diligence in the clinical trial space present during mergers and acquisitions (M&As).

  3. How Are Therapeutic Radiopharmaceuticals Advancing Precision Oncology? 11/7/2025

    By directing radioactive isotopes straight to diseased tissue, these agents deliver potent, localized treatment while sparing healthy cells — a major leap forward for patients with metastatic or treatment-resistant cancers.

  4. Highlights From The 2025 International Hepatitis B Meeting 11/7/2025

    For biotech and pharmaceutical teams, the core message was clear: progress is accelerating, but success still depends on smart study design, fit-for-purpose endpoints, and operational execution.

  5. How CROs, Sites, PIs, And Sponsors Work Better Together 11/7/2025

    Each role is critical, yet operating in isolation results in slower timelines, duplicated effort, and missed opportunities. When collaboration replaces coordination, trials gain speed, quality, and patient trust.

  6. The Trust Deficit: Is An Overlooked Literacy Gap Stalling Clinical Trial Enrollment? 11/7/2025

    Here, we examine the critical disconnect in a patient's understanding and how purpose-built AI platforms can translate complex medical language into plain, accessible communication.

  7. Sites Are 3X Likely To Die In The First Year Than New Businesses 11/7/2025

    Milken Institute Health Director of Research Andrew Friedson, Ph.D., reveals the stark truth of site survivability and discusses how factors like available population and local economic conditions factor into survival rates.

  8. How Emerging Technologies Are Challenging Traditional IRB Oversight 11/6/2025

    Uncover how sponsors, CROs, and study monitors can navigate FDA expectations and Institutional Review Board (IRB) requirements when integrating AI and Software-as-a-Medical-Device into clinical trials.

  9. How AI-Enhanced CAPA Systems Actually Work 11/6/2025

    Learn how AI can accelerate root cause analysis, predict quality risks, and streamline CAPA without compromising compliance or overwhelming your team with practical strategies.

  10. Sponsors Collect Too Much "Non-Essential" Data, Say Tufts And TransCelerate 11/6/2025

    A collaboration between Tufts CSDD, Tufts School of Medicine, and TransCelereate BioPharma revealed just how much extra data sponsors are collecting — and why that's a problem.